NCT00228358: Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine |
|
|
| Completed | 1 | 8 | US | ex vivo-expanded HER2-specific T cells, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, denileukin diftitox, DAB389 interleukin-2, DAB389 interleukin-2 immunotoxin, DAB389-IL2, DABIL2, flow cytometry, immunoenzyme technique, immunoenzyme techniques | University of Washington, National Cancer Institute (NCI) | HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor | 05/11 | | | |
